Afimoxifene
Information
- Drug Name
- Afimoxifene
- Description
- Entry(CIViC)
- 1
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| breast cancer |
FGFR1 AMPLIFICATION ( ENST00000425967.8 ) FGFR1 AMPLIFICATION ( ENST00000425967.8 ) |
D |
Predictive
|
Supports
|
Resistance | Somatic | 3 | 20179196 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| FGFR1-amplified breast cancer cell lines show resi... | FGFR1 |
FGFR1 AMPLIFICATION ( ENST00000425967.8 ) FGFR1 AMPLIFICATION ( ENST00000425967.8 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00952731 | Completed | Phase 2 | 4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ | December 2009 | |
| NCT03063619 | Completed | Phase 2 | Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast | January 30, 2018 | October 26, 2021 |
| NCT02993159 | Recruiting | Phase 2 | Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast | May 31, 2017 | July 15, 2023 |
| NCT04009044 | Recruiting | Phase 2 | Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast | February 17, 2020 | June 25, 2024 |